GNI Group

2160.TSE

24.07 USD

0.22

+0.92%

Overview

Last close

24.07 usd

Market cap

1.21B usd

52 week high

30.23 usd

52 week low

10.22 usd

Target price

31.17 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

8.1458

Price/Book Value

5.0579

Enterprise Value

1.12B usd

EV/Revenue

7.0451

EV/EBITDA

510.5823

Key financials

Revenue TTM

159.18M usd

Gross Profit TTM

120.66M usd

EBITDA TTM

-4.09M usd

Earnings per Share

-0.12 usd

Dividend

N/A usd

Total assets

456.11M usd

Net debt

-22.20M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.